Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 5/20 | 0.66 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.66 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.63 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.63 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | NPY1R | P25929 | 3/20 | 0.59 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.59 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.59 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | NPY4R | P50391 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 2/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352548 | 0.84 | KEAP1 (0.62) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL31339335 | 0.82 | AGTR2 (0.77) | AGTR2AGTR1 | |
| SCHEMBL29903379 | 0.81 | NTSR2 (0.58) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL29860571 | 0.80 | NTSR1 (0.58) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL29638302 | 0.80 | REN (0.62) | NTSR1NTSR2SORT1 | |
| SCHEMBL30512511 | 0.80 | MAPK8 (0.58) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL32660794 | 0.80 | NTSR1 (0.71) | NTSR1NTSR2SORT1NPY1RNMUR2 | |
| SCHEMBL29930119 | 0.80 | NTSR1 (0.87) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL31679466 | 0.79 | MAPK8 (0.57) | NTSR1NTSR2AGTR2AGTR1SORT1 | |
| SCHEMBL29416842 | 0.79 | NTSR1 (0.87) | NTSR1NTSR2SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536211-A2 | CONJUGATE TARGETING CARDIOVASCULAR DISEASE | Suntec Medical, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| CN-119677510-A | Conjugates for targeting cardiovascular disease | 欣扬生医股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-20250090683-A1 | CONJUGATE TARGETING CARDIOVASCULAR DISEASE | SUNTEC MEDICAL INC (US) | 2025-03-20 | — | — | US | claimed |
| WO-2023240035-A2 | CONJUGATE TARGETING CARDIOVASCULAR DISEASE | SUNTEC MEDICAL, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| EP-4725955-A1 | PEPTIDE TARGETING C-MET, PHARMACEUTICAL COMPOSITION COMPRISING SAID PEPTIDE AND USE THEREOF | Nanjing Anji Biotechnology Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4536211-A2 | CONJUGATE TARGETING CARDIOVASCULAR DISEASE | Suntec Medical, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119677510-A | Conjugates for targeting cardiovascular disease | 欣扬生医股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250090683-A1 | CONJUGATE TARGETING CARDIOVASCULAR DISEASE | SUNTEC MEDICAL INC (US) | 2025-03-20 | — | — | US | disclosed |
| CN-119613497-A | Composition containing probiotics and application of composition in oral cavity cleaning | 北京越思生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2025001851-A1 | PEPTIDE TARGETING C-MET, PHARMACEUTICAL COMPOSITION COMPRISING SAID PEPTIDE AND USE THEREOF | 南京安吉生物科技有限公司 | 2025-01-02 | — | — | WO | disclosed |
| WO-2023240035-A2 | CONJUGATE TARGETING CARDIOVASCULAR DISEASE | SUNTEC MEDICAL, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090683-A1 | CONJUGATE TARGETING CARDIOVASCULAR DISEASE | LIPG, PCSK9, VEGFA | NTSR1 2068/4885NTSR2 1859/4885AGTR2 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.